IPFSG salvage prognostic model
Which baseline and relapse characteristics predict outcomes after first salvage treatment for germ-cell tumours?
International mixed-GCT dataset; prognostic study, not a regimen trial
Study population as reported in the cited publication; cohort sizes and denominators are stated where available.
Not all evidence is randomized, comparative, or seminoma-specific.
Reported outcomes
The IPFSG model was developed from a large international retrospective cohort. In the full eligible cohort, 3-year PFS was 38% and overall survival was 51%; prognostic factors support risk-adapted salvage discussions.
Bars visualize source-reported percentages; where the denominator is shown, it is the observed count/denominator rather than a comparative treatment effect. NNT is not calculated for single-arm cohorts or non-randomized comparisons.
Interpretation and limitations
Guideline context: ESMO–EURACAN recommends standard-dose VIP/PEI, TIP or VeIP as conventional first salvage options after relapse following cisplatin-based chemotherapy. NCCN Testicular Cancer Guidelines Insights (Version 2.2025) is a contemporary US guideline source. The study summarized here is not necessarily seminoma-specific; histology scope is stated explicitly below.
Guidelines: ESMO–EURACAN 2022 · NCCN Insights v2.2025
Primary study source
International Prognostic Factors Study Group. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol. 2010;28:4906–4911.
Original study / PubMed / registry ↗
Evidence review date: 18 October 2026. Confirm regimen choice and dose schedules against current guideline text and an expert germ-cell tumour multidisciplinary team.